stockrowRevolution Medicines, Inc.
RVMD Healthcare Biotechnology
Revolution Medicines, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $11.6 million, down 67.3% from fiscal 2022.
- Revenue
- +1,188.7%
- EPS
- −17.7%
- Free cash flow
- −99.1%
- Total debt
- +313.3%
Quarter to September 2026, against a year earlier
Follow RVMD
Alert me
Revolution Medicines, Inc. (RVMD) EV/Sales
As of 6 November 2026, Revolution Medicines, Inc. (RVMD) trades at a EV/Sales of 185×. Over the past ten years it has ranged from −1.3× (March 2020) to 1,625× (August 2026); the current reading is higher than 71% of that period. That is above the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | 81.9× | 129.41% |
| FY2022 | 35.7× | (20.30%) |
| FY2021 | 44.8× | 9.30% |
| FY2020 | 41.0× | — |
| FY2019 | −0.9× | — |
| FY2018 | −0.9× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Sep 2026 | 199× | 142.57% |
| Dec 2023 | 81.9× | 20.38% |
| Jun 2023 | 68.0× | 96.92% |
| Mar 2023 | 34.5× | (3.22%) |
| 16 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| BNTX BioNTech SE Sponsored ADR compare | 1.9× |
| INCY Incyte Corporation compare | 3.4× |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 6.2× |
| GMAB Genmab A/S Sponsored ADR compare | 8.8× |
| ARGX argenex SE compare | 9.2× |
| RPRX Royalty Pharma PLC compare | 14.5× |
| INSM Insmed, Inc. compare | 16.2× |
| RVMD Revolution Medicines, Inc. | 185× |
| ROIV Roivant Sciences Ltd. compare | 3,255× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)
More on RVMD
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement